Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE…
News
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE…
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) — Centogene N.V….
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) — Centogene N.V….
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib…
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib…
GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research – MRFF Grant names GTG as sole Industry Partner
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice MELBOURNE, Australia, Sept. 11,…
GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research – MRFF Grant names GTG as sole Industry Partner
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice MELBOURNE, Australia, Sept. 11,…
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine development…
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine development…
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
MBX 2109 was observed to be generally well-tolerated MBX 2109 increased albumin adjusted serum calcium…
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
MBX 2109 was observed to be generally well-tolerated MBX 2109 increased albumin adjusted serum calcium…
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society…
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society…
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
Company to present BDTX-1535 dose escalation data in NSCLC at the AACR-NCI-EORTC Conference in October…
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
Company to present BDTX-1535 dose escalation data in NSCLC at the AACR-NCI-EORTC Conference in October…
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using…
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using…